Lmito Therapeutics Co., Ltd.

Lmito Therapeutics Co. , Ltd. focuses on developing innovative therapies to address autoinflammatory and autoimmune disorders, as well as fibrotic diseases, utilizing advanced metabolic reprogramming techniques. Founded in 2017, Lmito Therapeutics Co.

, Ltd. is headquartered in Seongnam, South Korea. The company specializes in therapeutic solutions for chronic inflammatory diseases and has secured Series A funding of KRW 7 billion in August 2020 from investors like DT&Investment, Kiwoom Investment, Stonebridge Ventures, and Yuanta Investment. The firm has completed one deal to date, indicating its focused investment strategy under the leadership of CEO Wheeseong Lee, who has a history of founding other companies in the sector.

Lmito Therapeutics specializes in developing innovative therapies that target autoinflammatory and autoimmune disorders, as well as fibrotic diseases, by reprogramming mitochondrial and cellular metabolism. Their core offerings address conditions such as Inflammatory Bowel Disease, Rheumatoid Arthritis, Interstitial Lung Disease, and neuroinflammatory disorders including Multiple Sclerosis and Amyotrophic Lateral Sclerosis. The company primarily serves healthcare providers and institutions, focusing on markets in North America and Europe where advanced therapeutic options are in demand. Lmito Therapeutics employs a direct-to-business model, collaborating with healthcare systems, research institutions, and pharmaceutical partners for the distribution of its products.

The revenue structure is supported by partnership agreements that include milestone payments and royalties based on product performance in clinical trials and market launches. While specific pricing details for flagship products are not disclosed, the agreements incentivize both development and commercialization, contributing to the company’s ongoing business transactions and growth in the healthcare sector. In August 2020, Lmito Therapeutics Co. , Ltd.

raised KRW 7 billion in Series A funding, which will be utilized to further develop and launch new therapeutic products targeting autoinflammatory and autoimmune disorders. The company plans to expand its market presence into additional regions in Europe and North America by 2023, aiming to enhance accessibility to its innovative therapies. Recent funding will support the advancement of clinical trials and the strategic establishment of partnerships to facilitate product distribution.